RAPT RAPT Therapeutics Inc.

19.77
-1.82  -8%
Previous Close 21.59
Open 20.48
Price To Book -3.85
Market Cap 480,995,876
Shares 24,329,584
Volume 155,585
Short Ratio
Av. Daily Volume 108,683
Stock charts supplied by TradingView

NewsSee all news

  1. RAPT Therapeutics Announces Upcoming Investor Conference Presentations

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  2. RAPT Therapeutics Announces Pricing of $75 Million Public Offering

    SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  3. RAPT Therapeutics Announces Proposed Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  4. RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  5. RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices

    SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b data due 3Q 2020.
RPT193
Atopic dermatitis
Phase 2 data due 2Q 2020.
FLX475 + Keytruda
Advanced Cancer

Latest News

  1. RAPT Therapeutics Announces Upcoming Investor Conference Presentations

    SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  2. RAPT Therapeutics Announces Pricing of $75 Million Public Offering

    SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  3. RAPT Therapeutics Announces Proposed Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  4. RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  5. RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices

    SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  6. RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  7. RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  8. RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

  9. RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia

    SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, Dec. 03, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering,